CDK4/6抑制剂通过调控三阴性乳腺癌免疫微环境促进抗肿瘤免疫的机制研究进展

国际肿瘤学杂志››2022,Vol. 49››Issue (6): 362-365.doi:10.3760/cma.j.cn371439-20211215-00069

CDK4/6抑制剂通过调控三阴性乳腺癌免疫微环境促进抗肿瘤免疫的机制研究进展

吴家宜¹, 陈柯羽¹, 邵喜英²(), 王晓稼²()

¹浙江中医药大学第二临床医学院,杭州 310053
²中国科学院大学附属肿瘤医院乳腺内科,杭州 310022

收稿日期:2021-12-15修回日期:2022-01-13出版日期:2022-06-08发布日期:2022-06-30
通讯作者:邵喜英,王晓稼,孔春燕 E-mail:shaoxy@zjcc.org.cn;wangxj@zjcc.org.cn
基金资助:
浙江省医药卫生科技计划(2021KY551)

Research progress on the mechanism of CDK4/6 inhibitors promoting antitumor immunity by regulating the immune microenvironment of triple negative breast cancer

Wu Jiayi¹, Chen Keyu¹, Shao Xiying²(), Wang Xiaojia²()

¹Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou 310053, China
²Department of Breast Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou 310022, China

Received:2021-12-15Revised:2022-01-13Online:2022-06-08Published:2022-06-30
Contact:Shao Xiying,Wang Xiaojia E-mail:shaoxy@zjcc.org.cn;wangxj@zjcc.org.cn
Supported by:
Medical Science and Technology Plan of Zhejiang Province of China(2021KY551)

摘要/Abstract

摘要：

三阴性乳腺癌是一种预后较差的乳腺癌亚型,缺乏有效的治疗手段。细胞周期蛋白依赖性激酶（CDK）4/6抑制剂能够通过影响三阴性乳腺癌免疫微环境促进抗肿瘤免疫,如提高肿瘤细胞表面程序性死亡蛋白配体-1蛋白表达、增强T细胞活化和抗原呈递、改变T细胞亚群比例、诱导淋巴细胞浸润等。免疫微环境的变化与肿瘤进展关系密切,但其机制极其复杂。探讨CDK4/6抑制剂影响免疫微环境的作用机制及相关的生物标志物,可为三阴性乳腺癌的诊治提供新的方向。

关键词:三阴性乳腺癌,肿瘤微环境,细胞周期,免疫检查点抑制剂

Abstract:

Triple negative breast cancer is a subtype of breast cancer with poor prognosis and lack of effective treatment. Cyclin dependent kinase（CDK）4/6 inhibitors promote antitumor immunity by influencing the triple negative breast cancer immune microenvironment, such as increasing the tumor cell surface pragrammed death-ligand 1 protein expression, enhancing T cell activation and antigen presentation, changing the proportion of T cell subgroup and inducing lymphocyte infiltration. The change of immune microenvironment is related to tumor progression, but its mechanism is extremely complex. Exploring the mechanism of CDK4/6 inhibitor affecting immune microenvironment and its biomarkers can provide a new direction for the diagnosis and treatment of triple negative breast cancer.

Key words:Triple negative breast neoplasms,Tumor microenvironment,Cell cycle,Immunocheckpoint inhibitors

吴家宜, 陈柯羽, 邵喜英, 王晓稼. CDK4/6抑制剂通过调控三阴性乳腺癌免疫微环境促进抗肿瘤免疫的机制研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 362-365.

Wu Jiayi, Chen Keyu, Shao Xiying, Wang Xiaojia. Research progress on the mechanism of CDK4/6 inhibitors promoting antitumor immunity by regulating the immune microenvironment of triple negative breast cancer[J]. Journal of International Oncology, 2022, 49(6): 362-365.

参考文献26

[1]	Shen M, Pan H, Chen Y, et al. A review of current progress in triple-negative breast cancer therapy[J]. Open Med (Wars), 2020, 15(1): 1143-1149. DOI: 10.1515/med-2020-0138. doi:10.1515/med-2020-0138
[2]	Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. DOI: 10.1016/S0140-6736(20)32531-9. doi:10.1016/S0140-6736(20)32531-9
[3]	de Melo Gagliato D, C Buzaid A, Perez-Garcia JM, et al. CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer: current practice and knowledge[J]. Cancers (Basel), 2020, 12(9): 2480. DOI: 10.3390/cancers12092480. doi:10.3390/cancers12092480
[4]	Roberts PJ, Kumarasamy V, Witkiewicz AK, et al. Chemotherapy and CDK4/6 inhibitors: unexpected bedfellows[J]. Mol Cancer Ther, 2020, 19(8): 1575-1588. DOI: 10.1158/1535-7163.MCT-18-1161. doi:10.1158/1535-7163.MCT-18-1161
[5]	Bonelli M, La Monica S, Fumarola C, et al. Multiple effects of CDK4/6 inhibition in cancer: from cell cycle arrest to immu-nomodulation[J]. Biochem Pharmacol, 2019, 170: 113676. DOI: 10.1016/j.bcp.2019.113676. doi:10.1016/j.bcp.2019.113676
[6]	Uzhachenko RV, Bharti V, Ouyang Z, et al. Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors[J]. Cell Rep, 2021, 35(1): 108944. DOI: 10.1016/j.celrep.2021.108944. doi:10.1016/j.celrep.2021.108944
[7]	Fleisher B, Lezeau J, Werkman C, et al. In vitro to clinical translation of combinatorial effects of doxorubicin and abemaciclib in Rb-positive triple negative breast cancer: a systems-based pharmacokinetic/pharmacodynamic modeling approach[J]. Breast Cancer (Dove Med Press), 2021, 13: 87-105. DOI: 10.2147/BCTT.S292161. doi:10.2147/BCTT.S292161
[8]	Franzoi MA, de Azambuja E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials-how to explain different results?[J]. ESMO Open, 2020, 5(6): e001112. DOI: 10.1136/esmoopen-2020-001112. doi:10.1136/esmoopen-2020-001112
[9]	Ameratunga M, Kipps E, Okines AFC, et al. To cycle or Fight-CDK4/6 inhibitors at the crossroads of anticancer immunity[J]. Clin Cancer Res, 2019, 25(1): 21-28. DOI: 10.1158/1078-0432.CCR-18-1999. doi:10.1158/1078-0432.CCR-18-1999pmid:30224338
[10]	Di Sante G, Pagé J, Jiao X, et al. Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology[J]. Expert Rev Anticancer Ther, 2019, 19(7): 569-587. DOI: 10.1080/14737140.2019.1615889. doi:10.1080/14737140.2019.1615889
[11]	Zhang J, Bu X, Wang H, et al. Cyclin D-CDK4 kinase desta-bilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance[J]. Nature, 2018, 553(7686): 91-95. DOI: 10.1038/nature25015. doi:10.1038/nature25015
[12]	Teh JLF, Aplin AE. Arrested developments: CDK4/6 inhibitor resis-tance and alterations in the tumor immune microenvironment[J]. Clin Cancer Res, 2019, 25(3): 921-927. DOI: 10.1158/1078-0432.CCR-18-1967. doi:10.1158/1078-0432.CCR-18-1967
[13]	Zhang QF, Li J, Jiang K, et al. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner[J]. Theranostics, 2020, 10(23): 10619-10633. DOI: 10.7150/thno.44871. doi:10.7150/thno.44871
[14]	Schaer DA, Beckmann RP, Dempsey JA, et al. The CDK4/6 inhi-bitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade[J]. Cell Rep, 2018, 22(11): 2978-2994. DOI: 10.1016/j.celrep.2018.02.053. doi:S2211-1247(18)30234-1pmid:29539425
[15]	Charles A, Bourne CM, Korontsvit T, et al. Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy[J]. Oncoimmunology, 2021, 10(1): 1916243. DOI: 10.1080/2162402X.2021.1916243. doi:10.1080/2162402X.2021.1916243
[16]	Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity[J]. Nature, 2017, 548(7668): 471-475. DOI: 10.1038/nature23465. doi:10.1038/nature23465
[17]	Petroni G, Formenti SC, Chen-Kiang S, et al. Immunomodulation by anticancer cell cycle inhibitors[J]. Nat Rev Immunol, 2020, 20(11): 669-679. DOI: 10.1038/s41577-020-0300-y. doi:10.1038/s41577-020-0300-y
[18]	Huang H, Zhou J, Chen H, et al. The immunomodulatory effects of endocrine therapy in breast cancer[J]. J Exp Clin Cancer Res, 2021, 40(1): 19. DOI: 10.1186/s13046-020-01788-4. doi:10.1186/s13046-020-01788-4
[19]	Heckler M, Ali LR, Clancy-Thompson E, et al. Inhibition of CDK4/6 promotes CD8 T-cell memory formation[J]. Cancer Discov, 2021, 11(10): 2564-2581. DOI: 10.1158/2159-8290.CD-20-1540. doi:10.1158/2159-8290.CD-20-1540pmid:33941591
[20]	Lai AY, Sorrentino JA, Dragnev KH, et al. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy[J]. J Immunother Cancer, 2020, 8(2): e000847. DOI: 10.1136/jitc-2020-000847. doi:10.1136/jitc-2020-000847
[21]	Sobhani N, D'Angelo A, Pittacolo M, et al. Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer[J]. Cells, 2019, 8(4): 321. DOI: 10.3390/cells8040321. doi:10.3390/cells8040321
[22]	Shen H, Yang ES, Conry M, et al. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies[J]. Genes Dis, 2019, 6(3): 232-246. DOI: 10.1016/j.gendis.2019.06.006. doi:10.1016/j.gendis.2019.06.006
[23]	Wang H, Najibi AJ, Sobral MC, et al. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors[J]. Nat Commun, 2020, 11(1): 5696. DOI: 10.1038/s41467-020-19540-z. doi:10.1038/s41467-020-19540-zpmid:33173046
[24]	Nedeljković M, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge[J]. Cells, 2019, 8(9): 957. DOI: 10.3390/cells8090957. doi:10.3390/cells8090957
[25]	Agostinetto E, Caparica R, Caparica E. CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?[J]. ESMO Open, 2020, 5(6): e001132. DOI: 10.1136/esmoopen-2020-001132. doi:10.1136/esmoopen-2020-001132
[26]	Volpari T, de Santis F, Bracken AP, et al. Anticancer innovative therapy: highlights from the ninth annual meeting[J]. Cytokine Growth Factor Rev, 2020, 51: 1-9. DOI: 10.1016/j.cytogfr.2019. 12.002. doi:10.1016/j.cytogfr.2019. 12.002